|Bid||50.41 x 1200|
|Ask||50.53 x 1300|
|Day's Range||49.85 - 50.65|
|52 Week Range||25.04 - 52.86|
|Beta (5Y Monthly)||0.32|
|PE Ratio (TTM)||829.34|
|Earnings Date||Nov 02, 2020 - Nov 06, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||52.64|
QIAGEN (QGEN) expands portfolio of automated testing solutions to address laboratory needs in almost any setting for molecular diagnostics via the completed buyout of NeuMoDx.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248 million in cash. The move rounds out QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology.
Intuit, Gildan Activewear, Barrick Gold, QIAGEN and AngloGold Ashanti highlighted as Zacks Bull and Bear of the Day